Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from MRNA

MRNA Stock Gets a Shot in the Arm as FDA Approves Moderna Flu Vaccine

Moderna has secured FDA approval for its flu vaccine mFLUSIVA. But does that warrant buying MRNA shares today? Let’s find out!

Barchart

Are Wall Street Analysts Predicting Moderna Stock Will Climb or Sink?

Despite Moderna's stellar outperformance over the past year, Wall Street analysts remain cautious about the stock's longer-term prospects.

Barchart

Earnings Preview: What To Expect From Moderna’s Report

Moderna is likely to announce its fiscal second-quarter earnings by the end of this month, and analysts expect its losses to narrow.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

MarketBeat Week in Review – 06/29 - 07/03

MarketBeat's weekly roundup covers a weaker June jobs report, tech sector rotation, and top analyst picks including TSLA, AVGO, PLTR, MRNA, and NEE heading into Q2 earnings season.

MarketBeat

Short Squeeze Alert—Moderna Stock Surges on New Strategy

Moderna shares rose nearly 20% after Science Day, driven partly by a short squeeze, while its mRNA pipeline beyond vaccines faces a multi-year path to revenue.

MarketBeat

MRNA Stock Spikes as Moderna Shares mRNA Pipeline Update

Moderna stock soars on positive updates during the Science Day presentation. Jefferies sees significant further upside in MRNA shares.

Barchart

Moderna Stock: Is MRNA Outperforming the Health Care Sector?

Although Moderna has outperformed the broader health care sector over the last 12 months, analysts maintain a cautious stance on the stock’s future outlook.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Moderna Stock Is Surging on Hantavirus Threats. Its Chart Offers a Harsh Dose of Reality.

A localized outbreak, even a fatal one, is unlikely to spark the multibillion-dollar revenue catalyst that Moderna needs.

Barchart

Is Wall Street Bullish or Bearish on Moderna Stock?

Moderna has notably outperformed the broader market over the past year, yet Wall Street analysts maintain a cautious outlook about the stock’s prospects.

Barchart

Moderna's Quarterly Earnings Preview: What You Need to Know

Moderna is expected to announce its fiscal first-quarter earnings next month, and analysts project a high single-digit decline in losses.

Barchart

Moderna Is Most Shorted S&P 500 Stock Now. Is It a Contrarian Buy?

Moderna is the most shorted S&P 500 stock, with 17.8% short float. But its cancer pipeline, flu approval, and international contracts may surprise bears in 2026.

Barchart

The S&P 500's 3 Best-Performing Stocks So Far in 2026

Despite a broad market selloff, SNDK, TPL, and MRNA stand out as the S&P 500's 3 best-performing stocks in 2026, each operating in a different sector.

MarketBeat

Is Moderna Stock Outperforming the Dow?

Moderna has outperformed the Dow over the past year, yet Wall Street analysts maintain a cautious outlook on the stock’s prospects.

Barchart

Moderna Jumps Above 20-Day Moving Average on FDA Flu Vaccine Review. Should You Buy MRNA Stock Here?

Moderna shares extend gains as FDA reverses its refusal-to-file decision on the firm’s influenza vaccine. Here’s why MRNA shares still aren’t attractive to own in 2026.

Barchart

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Can This Former Pandemic Star Make a Stunning Comeback?

Moderna is betting its mRNA pipeline can power the next growth cycle.

Barchart

Are Wall Street Analysts Bullish on Moderna Stock?

While Moderna has outpaced the S&P 500 over the past year, Wall Street analysts maintain a cautious outlook about the stock’s prospects.

MarketBeat

3 ETFs Catapulting Beyond the S&P to Start the Year

Three ETFs with year-to-date performance of 30% or better include a fund focused on drone technology, one targeting nickel miners, and a covered call play.

MarketBeat

MarketBeat Week in Review – 01/19 - 01/23

Stocks rallied after a sharp sell-off as economic indicators pointed to a growing economy; next week may bring more volatility as "big tech" begins to report.

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

Moderna Pops 17%—Is There Life in MRNA, Down 90% from COVID High?

COVID-19 vaccine stock Moderna just got its biggest lift in recent memory, moving up 17%. Can MRNA stage a broader recovery, down +90% from its all-time high?

Barchart

Moderna's Q4 2025 Earnings: What to Expect

Moderna will release its fourth-quarter earnings soon, and analysts anticipate a low double-digit loss decline.

Kiplinger

Nasdaq Leads as Tech Stages Late-Week Comeback: Stock Market Today

Oracle stock boosted the tech sector on Friday after the company became co-owner of TikTok's U.S. operations.

Barchart

Is Moderna Stock Underperforming the Nasdaq?

Moderna has continued to underperform the Nasdaq Composite over the past year, and analysts remain cautious about the stock’s prospects.

Benzinga

mRNA Vaccine Maker Moderna Lowers R&D Spending, Tightens Sales Forecast

Moderna Inc. (NASDAQ:MRNA) reported a third-quarter loss of 51 cents, beating the expected loss of $2.02, a turnaround from an income of 3 cents a year ago.

Benzinga

Moderna Q3 2025 Earnings Call Transcript

Moderna, Inc (NASDAQ:MRNA) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below. MRNA is building positive momentum. Watch the momentum here This transcript is brought to you by Benzinga APIs. For real-time access to our entire catalog, please visithttps://www.benzinga.com/apis/for a consultation. Operator…

Benzinga

Moderna Stops CMV Program As Vaccine Falls Short In Preventing Infection

Moderna, Inc. (NASDAQ:MRNA) revealed topline results on Wednesday from a Phase 3 trial evaluating the efficacy of mRNA-1647, the company’s investigational cytomegalovirus (CMV) vaccine. CMV is a herpes virus. Those who are pregnant or have compromised immune systems are most at risk from CMV.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Advanced Micro Devices

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.